Vitality Watch

Dossier pubmed review 15-sep-2026
Narrative review or expert overview without new data

Reprogramming the Aging Type H Vascular Niche via Myeloid Angiogenic Cell-Derived Extracellular Vesicles: Mechanisms, Engineering Strategies, and Translational Perspectives.

Key claim: Myeloid angiogenic cell-derived extracellular vesicles can reprogram the aging Type H vascular niche to restore angiogenic-osteogenic coupling, with preconditioning, cargo engineering, targeting, and scaffold delivery proposed to overcome senescence-associated EV liabilities in age-related osteoporosis.

Abstract

Age-related osteoporosis is characterized by the simultaneous loss of bone mass and the regression of CD31Emcn(Type H) vessels, a specialized capillary subtype that functionally couples angiogenesis with osteogenesis. The endothelial progenitor cell (EPC) compartment, comprising myeloid angiogenic cells (MACs) and endothelial colony-forming cells (ECFCs), contributes to the maintenance of this vascular niche; however, its regenerative potential declines with age, partly as a consequence of cellular senescence and acquisition of the senescence-associated secretory phenotype (SASP). Given the clinical hurdles of conventional cell transplantation, therapeutic development has shifted toward cell-free strategies based on the MAC/ECFC secretome, particularly extracellular vesicles (EVs). In this review, we clarify the distinction between MACs and ECFCs to resolve historical conceptual ambiguities, and examine how their paracrine cues regulate angiogenic-osteogenic coupling. We then synthesize current evidence on endothelial EV cargo and discuss how aging remodels vesicle composition and function to drive vascular-bone uncoupling. Beyond existing reviews on EPC-EVs, Type H vessels, or EV-based bone regeneration, we add a protocol-driven re-annotation and explicitly distinguish bone-related studies methodologically compatible with MAC-derived EVs from adjacent evidence using other endothelial cell sources and mechanistic support from non-skeletal models. Finally, we compare bioengineering strategies, including preconditioning, precision cargo engineering, surface targeting, and scaffold/hydrogel delivery, aimed at correcting senescence-associated cargo liabilities and improving translational readiness.

Why this matters

Bone loss and vascular aging are usually tracked on separate trend pages, but this review reframes them as one problem — Type H capillaries that couple angiogenesis to osteogenesis decay with age, and the EVs shed by aging endothelial progenitors carry senescence-associated cargo that fails to rejuvenate the niche. It is a mechanism-plausible synthesis (mechanism-plausible tier) that clarifies MAC vs ECFC identity confusion in the exosome-therapy space and enumerates engineering fixes; no clinical outcomes are demonstrated, and the translational claims outrun the primary data.

Source

Link

Briefing card

Reprogramming the Aging Type H Vascular Niche via Myeloid Angiogenic Cell-Derived Extracellular Vesicles: Mechanisms, Engineering Strategies, and Translational Perspectives.
Stage: review · pubmed · 15-sep-2026

Applies to preclinical EV-based osteoporosis programs and companies pitching myeloid/endothelial EV therapies — the biology remains model-organism and review-level, with no human efficacy data yet.

Myeloid angiogenic cell-derived extracellular vesicles can reprogram the aging Type H vascular niche to restore angiogenic-osteogenic coupling, with preconditioning, cargo engineering, targeting, and scaffold delivery proposed to overcome senescence-associated EV liabilities in age-related osteoporosis.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.3390/ijms27188202

build build 880 · 2bcef25 · 2026-11-18